Vitamin B6 injection of China Resources Double Crane subsidiary passed the consistency evaluation
April 24, 2025
Source: drugdu
60
On April 22, China Resources Double Crane(600062) announced that its wholly-owned subsidiary China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received a VitaminB6 Injection "Notice of Approval of Drug Supplementary Application".
The drug has passed the generic drug quality and efficacy consistency evaluation, and has added a supplementary application for the 1ml:100mg specification. The approval of this consistency evaluation will be beneficial to the company's market sales and competitiveness.
As of the announcement date, Shuanghe Limin has invested 3.89 million yuan in the consistency evaluation of the drug. According to market data, the global sales of vitamin B6 injection will be 47.17 million US dollars in 2023, of which the total sales in the Chinese market will be 453 million yuan.
In 2024, China Resources Double-Crane achieved revenue of 11.212 billion yuan and net profit attributable to shareholders of the parent company of 1.628 billion yuan.
https://finance.eastmoney.com/a/202504223384473457.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Fudan University establishes the “Baili Tianheng Distinguished Professor” program May 14, 2025
- If you don’t lower, don’t sell! Trump enforces minimum drug prices in developed countries, but litigation war may ‘repeat’ May 14, 2025
- Barriers and Pathways to Healthtech Adoption in Clinical Practice May 14, 2025
- US Health Officials Advise Older Travelers Not to Get a Chikungunya Vaccine May 14, 2025
- Laimi Pharmaceuticals receives approval for supplemental application for naloxone hydrochloride injection May 14, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
